Last updated on October 2018

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer


Brief description of study

The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.

Clinical Study Identifier: NCT02907918

Contact Investigators or Research Sites near you

Start Over

Foluso O Ademuyiwa, M.D., MPH

St. Elizabeth Physicians
Edgewood, KY United States
  Connect »

Foluso O Ademuyiwa, M.D., MPH

Washington University School of Medicine
Saint Louis, MO United States
  Connect »

Gary Unzeitig, M.D.

Doctor's Hospital of Laredo
Laredo, TX United States
  Connect »

Kathy D Miller, M.D.

Indiana University Health Melvin and Bren Simon Cancer Center
Bloomington, IN United States
  Connect »

Ellis Levine, M.D.

Roswell Park Cancer Institute
Buffalo, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.